Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03602677
Other study ID # ICG-COLORAL
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 24, 2018
Est. completion date December 1, 2023

Study information

Verified date March 2023
Source Oulu University Hospital
Contact Jyrki Kössi, MD, PhD
Phone +358381911
Email jyrki.kossi@phhyky.fi
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, controlled, parallel, multicenter trial to determine the difference in post-operative anastomotic leakages in colorectal surgery, where anastomosis perfusion is evaluated using indocyanine green fluorescence imaging as an addition to standard surgical practice compared to surgical practice alone.


Recruitment information / eligibility

Status Recruiting
Enrollment 1062
Est. completion date December 1, 2023
Est. primary completion date July 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - All consenting patients in the catchment area of participating hospitals who undergo elective colorectal surgery with planned primary anastomosis are eligible for this study. - Of rectal cancer patients only those with pathology in the proximal third will be included in the study (defined by area proximal from peritoneal fold). Exclusion Criteria: - Emergent patients - Patients with proven diverticular abscess and colonic fistulas are excluded - Patients with planned open surgery are excluded.

Study Design


Intervention

Device:
ICG fluorescence imaging
The use of indocyanine green fluorescence imaging as an addition to standard surgical procedure.

Locations

Country Name City State
Finland Central Finland Central Hospital Jyväskylä
Finland Päijät Häme Central Hospital Lahti

Sponsors (8)

Lead Sponsor Collaborator
Oulu University Hospital Central Finland Hospital District, Hospital District of Helsinki and Uusimaa, Päijänne Tavastia Central Hospital, Seinäjoki Central Hospital, Seinäjoki, Finland, Tampere University Hospital, Turku University Hospital, University of Oulu

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Anastomosis leakage rate 0 to 90 days
Secondary Severity of anastomosis leakage Grade A-C according to International Study Group of Rectal Cancer 0 to 90 days
Secondary Timing of anastomosis leakage Days 0 to 90 days
Secondary Deep surgical site infections Yes/no 0 to 90 days
Secondary Hospital readmission rate 0 to 90 days
Secondary Reoperation rate 0 to 90 days
Secondary 30- and 90-day complications according to Clavien-Dindo Classification Clavien-Dindo Score from Grade 0 (no complications) to Grade V (Death of a patient). Five grades and additionally Grade III and IV will be divided to a and b. 0 to 90 days
Secondary Operation time Time from the start of the operation until the surgeon has ended the operation 0-600 minutes
Secondary Length of hospital stay Day of the operation is considered the day 0 0-365 days
Secondary 30- and 90-day mortality 0 to 90 days
Secondary Time to first bowel movement Postoperative day when the first bowel movement occurs 0-30 days
Secondary Time to first flatus Postoperative day when the first flatus occurs 0-30 days
Secondary Hospital costs 0 to 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A